Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 4/2021

01.04.2021 | Immunotherapy and Immunomodulators (B Vickery, Section Editor)

How to Incorporate Oral Immunotherapy into Your Clinical Practice

verfasst von: Elissa M. Abrams, Stephanie C. Erdle, Scott B. Cameron, Lianne Soller, Edmond S. Chan

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to discuss how to best incorporate oral immunotherapy into your clinical practice based on recent evidence and guidelines, and address controversies.

Recent Findings

Oral immunotherapy is the food immunotherapy treatment with the most literature supporting its use. Recent data from both randomized clinical trials and real-world studies show OIT is especially safe and effective in preschoolers, while avoidance may be less safe than previously thought. OIT guidelines support its use outside of research.

Summary

Oral immunotherapy can be safely and effectively incorporated into your clinical practice, with careful planning and consideration of scenarios where benefits outweigh risks. Baseline oral food challenges are necessary in clinical trials, but in clinical practice, these are best done when the history is unclear due to resource limitations. There is a role for both regular food and FDA-approved products. Future research should focus on optimizing safety and adherence in the real-world setting.
Literatur
1.
Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 SUPPL. 2):S116–25.PubMedCrossRef
2.
Soller L, Ben-Shoshan M, Harrington DW, Fragapane J, Joseph L, St Pierre Y, et al. Overall prevalence of self-reported food allergy in Canada. J Allergy Clin Immunol. 2012;130(4):986–8.PubMedCrossRef
3.
Clarke AE, Elliott S, Pierre YS, Soller L, La Vieille S, Ben-Shoshan M. Temporal trends in prevalence of food allergy in Canada. J Allergy Clin Immunol Pr. 2019
4.
Sicherer SH, Wood RA. Advances in diagnosing peanut allergy. J Allergy Clin Immunol Pr. 2013;1(1):1–13 quiz 14.CrossRef
5.
Flokstra-de Blok BMJ, Dubois AEJ, Vlieg-Boerstra BJ, Oude Elberink JNG, Raat H, DunnGalvin A, et al. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010;65(2):238–44.PubMedCrossRef
6.
Vickery BP, Ebisawa M, Shreffler WG, Wood RA. Current and future treatment of peanut allergy. J Allergy Clin Immunol Pr. 2019;7(2):357–65.CrossRef
7.
Warren CM, Otto AK, Walkner MM, Gupta RS. Quality of life among food allergic patients and their caregivers. Curr Allergy Asthma Rep. 2016;16(5):38.PubMedCrossRef
8.
Tang MLK, Lozinsky AC, Loke P. Peanut oral immunotherapy: state of the art. Immunol Allergy Clin N Am. 2020;40(1):97–110.CrossRef
9.
Baker MG, Wang J. Could this be it? Epicutaneous, sublingual, and subcutaneous immunotherapy for the treatment of food allergies. Curr Allergy Asthma Rep. 2019;19(11):53.PubMedCrossRef
10.
Waldron J, Kim EH. Sublingual and patch immunotherapy for food allergy. Immunol Allergy Clin N Am. 2020;40(1):135–48.CrossRef
11.
Chipps BE, Ciaccio CE, Rosen K, Haselkorn T, Zigmont E, Casale TB. Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology. J Allergy Clin Immunol Pr. 2019;7(2):721–723.e9.CrossRef
12.
•• Bird JA, Spergel JM, Jones SM, Rachid R, Assaad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2017;6(2):476–485.e3 COMMENT: Largest randomized controlled trial on OIT in children and adults.PubMedCrossRef
13.
•• Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–181.e8 COMMENT: First randomized trial of preschool OIT, showing the highest safety/efficacy for OIT to date.PubMedCrossRef
14.
Hsiao K-C, Ponsonby A-L, Axelrad C, Pitkin S, Tang MLK, Burks W, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2017;1(2):97–105.PubMedCrossRef
15.
Liat N. R. GM, Yitzhak K, B. LM, Arnon E. Long-term outcome of peanut oral immunotherapy—real-life experience. Pediatr Allergy Immunol. 2018;29(5):519–26.CrossRef
16.
Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immunol Pr. 2019;7(2):418–426.e4.CrossRef
17.
Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pr. 2019;7(2):479–491.e10.CrossRef
18.
Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.PubMedCrossRef
19.
Soller L, Abrams EM, Chan ES. An update on the controversy around offering oral immunotherapy to peanut-allergic children outside of research. Ann Allergy Asthma Immunol. 2019.
20.
•• Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First real-world safety analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pr. 2019. COMMENT: Largest pragmatic safety study of preschool peanut OIT.
21.
Tang MLK, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–744.e8.PubMedCrossRef
22.
•• Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Lidman PG, et al. First real-world effectiveness analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pr. 2020;145(2):AB72 COMMENT: Largest pragmatic effectiveness study of preschool peanut OIT.CrossRef
23.
Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72(8):1133–47.PubMedCrossRef
24.
Chu D, Wood R, French S, Fiocchi A, Jordana A. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222–32.PubMedCrossRef
25.
Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pr. 2019;7(2):429–436.e2.CrossRef
26.
Lucendo AJ, Arias Á, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9.PubMedCrossRef
27.
Erdle SC, Soller L, Avinashi V, Roberts H, Hsu E, Chan ES. Multiple shifting phenotypes with cow’s milk: from eosinophilic esophagitis to immediate hypersensitivity and back again. J Allergy Clin Immunol Pr. 2020;8(3):1117–8.CrossRef
28.
Cherkaoui S, Ben-Shoshan M, Alizadehfar R, Asai Y, Chan E, Cheuk S, et al. Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy. Clin Transl Allergy. 2015;5:16.PubMedPubMedCentralCrossRef
29.
Kansen HM, Le T-M, Knulst AC, Gorissen DMW, van der Ent CK, Meijer Y, et al. Three-year follow-up after peanut food challenges: accidental reactions in allergic children and introduction failure in tolerant children. J Allergy Clin Immunol. 2020;145(2):705–707.e7.PubMedCrossRef
30.
•• Begin P, Chan ES, Kim H, Wagner M, Cellier MS, Favron-Godbout C, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy, Asthma Clin Immunol. 2020;16:20 COMMENT: First North American clinical practice guideline on OIT.CrossRef
31.
Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy: European Journal of Allergy and Clinical Immunology. 2017
32.
Neuman-Sunshine DL, Eckman JA, Keet CA, Matsui EC, Peng RD, Lenehan PJ, et al. The natural history of persistent peanut allergy. Ann Allergy Asthma Immunol. 2012;108(5):326–31.PubMedCrossRef
33.
Somers LS. Peanut allergy: case of an 11-year-old boy with a selective diet. J Am Diet Assoc. 2011;111(2):301–6.PubMedCrossRef
34.
Jones SM, Scurlock AM. The impact of food allergy: the real “fear factor”. Ann Allergy Asthma Immunol. 2006;96(3):385–6.PubMedCrossRef
35.
Salmivesi S, Korppi M. The time has come to stop placebo-controlled trials of milk oral immunotherapy and focus on real-life studies. Vol. 107, Acta paediatrica (Oslo, Norway : 1992). Norway; 2018. p. 1855–6.
36.
Greenhawt MJ, Vickery BP. Allergist-reported trends in the practice of food allergen oral immunotherapy. J Allergy Clin Immunol Pr. 2015;3(1):33–8.CrossRef
37.
Blaiss MS, Tilles S, Petroni D, Zigmont E, Cassese M, Kwak B, et al. Current management and use of oral immunotherapy in the United States for patients with peanut allergy. Allergy Asthma Proc. 2019;40(4):214–20.PubMedCrossRef
38.
Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. J Allergy Clin Immunol. 2018;141:1–9.PubMedCrossRef
39.
Thyagarajan A, Varshney P, Jones SM, Sicherer S, Wood R, Vickery BP, et al. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol. 2010;126(1):31–2.PubMedPubMedCentralCrossRef
40.
Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286–291.e6.PubMedPubMedCentralCrossRef
41.
Wood RA, Sampson HA. Oral immunotherapy for the treatment of peanut allergy: is it ready for prime time? J Allergy Clin Immunol: In Practice. 2014;2(1):97–8.
42.
Greenhawt MJ. Oral and sublingual peanut immunotherapy is not ready for general use. In: Allergy and asthma proceedings. 2013. p. 197–204.
43.
Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 0):S1–58.PubMedPubMedCentral
44.
Nurmatov U, Venderbosch I, Devereux G, Simons FER, Sheikh A. Allergen-specific oral immunotherapy for peanut allergy. In: Cochrane database of systematic reviews. 2012.
45.
Mansfield LE. Oral immunotherapy for peanut allergy in clinical practice is ready. Allergy Asthma Proc. 2013;34(3):205–9.PubMedCrossRef
46.
Shaker MS, Schwartz J, Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29(4):497–502.PubMedCrossRef
47.
Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol. 2012;109(5):348–352.e2.PubMedCrossRef
48.
Dunn Galvin A, McMahon S, Ponsonby A-L, Hsiao K-C, Tang MLK. PPOIT study team. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy. 2018;73(3):560–8.PubMedCrossRef
49.
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304.PubMedPubMedCentralCrossRef
50.
Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, et al. Oral Immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. J Allergy Clin Immunol Pract. 2014;2(1):91–96.e2.PubMedCrossRef
51.
Traister RS, Green TD, Mitchell L, Greenhawt M. Community opinions regarding oral immunotherapy for food allergies. Ann Allergy Asthma Immunol. 2012;109(5):319–23.PubMedCrossRef
52.
Wasserman RL, Jones DH, Windom HH. Oral immunotherapy for food allergy-the FAST perspective. Ann Allergy Asthma Immunol. 2018
53.
Dunlop JH. Goals and motivations of families pursuing oral immunotherapy for food allergy. J Allergy Clin Immunol. 2018
54.
55.
MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–881.e8.PubMedCrossRef
56.
Syed A, Garcia MA, Lyu S-C, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10.PubMedPubMedCentralCrossRef
57.
Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval Rivas M, et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–1317.e6.PubMedPubMedCentralCrossRef
Metadaten
Titel
How to Incorporate Oral Immunotherapy into Your Clinical Practice
verfasst von
Elissa M. Abrams
Stephanie C. Erdle
Scott B. Cameron
Lianne Soller
Edmond S. Chan
Publikationsdatum
01.04.2021
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 4/2021
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-021-01009-8

Weitere Artikel der Ausgabe 4/2021

Current Allergy and Asthma Reports 4/2021 Zur Ausgabe

Rhinosinusitis (J Mullol, Section Editor)

The COVID-19 Pandemic—an Epidemiological Perspective

Occupational Allergies (JA Poole, Section Editor)

Nutritional Factors in Occupational Lung Disease

Autoimmunity (TK Tarrant, Section Editor)

Paget’s Disease of Bone: Osteoimmunology and Osteoclast Pathology

Occupational Allergies (JA Poole, Section Editor)

What Is New in Occupational Allergic Contact Dermatitis in the Year of the COVID Pandemic?

Rhinosinusitis (J Mullol, Section Editor)

Herbal Medicines for Allergic Rhinitis: a Systematic Review and Meta-analysis

Rhinosinusitis (J Mullol, Section Editor)

Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise